In this episode of Don't Miss a Beat, hosts offer a breakdown of 3 trials of note from the upcoming ESC Congress 2023 and provide context around the recent announcement of topline results from the SELECT trial.
It s all exploratory, but asundexian given with antiplatelets showed safe nuanced potential against poststroke recurrent events and quashed circulating factor XIa after stenting for acute MI.